Total Payments
$579,907
2024 Payments
$48,164
Companies
67
Transactions
2,221
Medicare Patients
12,104
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$470,247 (81.1%)
Travel$51,509 (8.9%)
Food & Beverage$35,335 (6.1%)
Consulting$20,483 (3.5%)
Research$2,062 (0.4%)
Education$211.72 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $470,247 | 339 | 81.1% |
| Travel and Lodging | $51,509 | 151 | 8.9% |
| Food and Beverage | $35,335 | 1,696 | 6.1% |
| Consulting Fee | $20,483 | 9 | 3.5% |
| Unspecified | $2,062 | 3 | 0.4% |
| Education | $211.72 | 22 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Payments by Type
General
$577,845
2,218 transactions
Research
$2,062
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $266,758 | 471 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $62,695 | 143 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $55,300 | 136 | $0 (2024) |
| Novo Nordisk Inc | $54,578 | 304 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $49,712 | 141 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $34,187 | 99 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $32,168 | 78 | $0 (2020) |
| Medtronic MiniMed, Inc. | $9,023 | 92 | $0 (2020) |
| ABBVIE INC. | $2,015 | 51 | $0 (2024) |
| Eli Lilly and Company | $1,823 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,164 | 213 | Lilly USA, LLC ($38,565) |
| 2023 | $58,909 | 239 | Lilly USA, LLC ($51,523) |
| 2022 | $42,653 | 282 | Lilly USA, LLC ($26,804) |
| 2021 | $30,597 | 231 | Lilly USA, LLC ($14,498) |
| 2020 | $57,093 | 246 | Lilly USA, LLC ($31,894) |
| 2019 | $109,095 | 344 | Lilly USA, LLC ($36,172) |
| 2018 | $112,969 | 321 | Lilly USA, LLC ($23,127) |
| 2017 | $120,427 | 345 | Lilly USA, LLC ($44,174) |
All Payment Transactions
2,221 individual payment records from CMS Open Payments — Page 1 of 89
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: Diabetes Care | ||||||
| 12/23/2024 | Seqirus USA Inc | Flucelvax (Biological), Fluad | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: Vaccines | ||||||
| 12/20/2024 | Neurocrine Biosciences, Inc. | CRENESSITY (Drug) | Food and Beverage | In-kind items and services | $34.75 | General |
| Category: Neuropsychiatry | ||||||
| 12/16/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: Durable Pump | ||||||
| 12/13/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Bone Health | ||||||
| 12/12/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $25.65 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/12/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $8.00 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Diabetes Care | ||||||
| 12/04/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $6.59 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: Endocrinology | ||||||
| 11/22/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $22.97 | General |
| 11/21/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $13.17 | General |
| Category: Insulin Pump | ||||||
| 11/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Endocrinology | ||||||
| 11/11/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: DIABETES | ||||||
| 10/30/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $28.85 | General |
| Category: Rare Disease | ||||||
| 10/28/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 10/23/2024 | Eli Lilly and Company | — | — | In-kind items and services | $1,823.27 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN ADULTS WITH CHRONIC KIDNEY DISEASE | ||||||
| 10/23/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $26.97 | General |
| Category: Endocrinology | ||||||
| 10/14/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $16.98 | General |
| Category: Insulin Pump | ||||||
| 10/10/2024 | Ultragenyx Pharmaceutical Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: XLH Metabolic Bone Disorder | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN ADULTS WITH CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $1,823 | 1 |
| Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type | SANOFI US SERVICES INC. | $239.03 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,679 | 4,672 | $463,355 | $224,261 |
| 2022 | 19 | 2,930 | 5,133 | $492,790 | $242,750 |
| 2021 | 19 | 3,170 | 5,709 | $584,385 | $299,952 |
| 2020 | 19 | 3,325 | 5,951 | $705,270 | $294,744 |
Total Patients
12,104
Total Services
21,465
Medicare Billing
$1.1M
Procedure Codes
74
All Medicare Procedures & Services
74 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 410 | 824 | $133,925 | $72,399 | 54.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 485 | 743 | $83,570 | $46,114 | 55.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 132 | 667 | $45,300 | $25,282 | 55.8% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 161 | 183 | $55,815 | $18,379 | 32.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 129 | 129 | $29,935 | $14,266 | 47.7% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 137 | 147 | $34,545 | $11,515 | 33.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 143 | 154 | $17,130 | $9,277 | 54.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 226 | 352 | $25,450 | $8,619 | 33.9% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2023 | 336 | 620 | $11,420 | $5,826 | 51.0% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2023 | 48 | 51 | $11,475 | $5,238 | 45.6% |
| 82947 | Blood glucose (sugar) level | Office | 2023 | 304 | 612 | $6,120 | $2,337 | 38.2% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 50 | 50 | $2,250 | $1,523 | 67.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 47 | 47 | $1,645 | $1,381 | 84.0% |
| 10006 | Fine needle aspiration biopsy using ultrasound guidance, each additional growth | Office | 2023 | 20 | 28 | $2,800 | $1,291 | 46.1% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 11 | 11 | $850.00 | $387.09 | 45.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 39 | $975.00 | $349.80 | 35.9% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 14 | 15 | $150.00 | $76.20 | 50.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 423 | 780 | $122,530 | $66,650 | 54.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 562 | 943 | $103,730 | $59,241 | 57.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 120 | 723 | $42,155 | $21,704 | 51.5% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 163 | 179 | $54,595 | $18,189 | 33.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 132 | 132 | $30,360 | $14,673 | 48.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 129 | 135 | $26,325 | $14,108 | 53.6% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 166 | 175 | $41,125 | $14,069 | 34.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 238 | 384 | $26,880 | $9,866 | 36.7% |
About Dr. Jamal Hammoud, M.D
Dr. Jamal Hammoud, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Flint, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639284672.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jamal Hammoud, M.D has received a total of $579,907 in payments from pharmaceutical and medical device companies, with $48,164 received in 2024. These payments were reported across 2,221 transactions from 67 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($470,247).
As a Medicare-enrolled provider, Hammoud has provided services to 12,104 Medicare beneficiaries, totaling 21,465 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 74 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Flint, MI
- Active Since 08/20/2006
- Last Updated 12/14/2018
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639284672
Products in Payments
- TRULICITY (Drug) $125,434
- JARDIANCE (Drug) $85,590
- MOUNJARO (Drug) $80,361
- FARXIGA (Drug) $50,139
- INVOKANA (Drug) $32,060
- SOLIQUA (Drug) $19,385
- Tresiba (Drug) $18,384
- JANUVIA (Drug) $16,559
- STEGLATRO (Drug) $14,249
- BYDUREON (Drug) $12,520
- Victoza (Drug) $11,502
- SOLIQUA 100/33 (Drug) $11,180
- TOUJEO (Drug) $11,151
- Ozempic (Drug) $10,152
- Minimed 630G (Device) $5,733
- iPro2 (Device) $2,506
- TOUJEO (Biological) $1,852
- Korlym (Drug) $1,586
- Androgel (Drug) $1,425
- SOLIQUA 100/33 (Biological) $1,064
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.